SGLT-2抑制剂联合RAASi治疗糖尿病肾病的研究进展  

Research Progress of SGLT-2 Inhibitor Combined with RAASi in the Treatment of Diabetic Nephropathy

作　　者：罗雪婷 肖厚勤 朱丹琦 LUO Xue-ting;XIAO Hou-qin;ZHU Dan-qi(The First Clinical Medical College of Jinan University,Guangzhou,Guangdong Province,510630 China;Department of Nephrology,Binhaiwan Central Hospital,Dongguan,Guangdong Province,523900 China)

机构地区：[1]暨南大学第一临床医学院,广东广州510630 [2]东莞市滨海湾中心医院肾脏内科,广东东莞523900

出　　处：《糖尿病新世界》2020年第21期194-198,共5页Diabetes New World Magazine

摘　　要：糖尿病肾病是糖尿病的严重并发症之一,是导致终末期肾脏病的常见原因。肾素-血管紧张素-醛固酮系统抑制剂(RAASi)已成为CKD的常规治疗,SGLT-2抑制剂是一种新型降糖药物,近年来发现其在肾脏和心脏方面的获益,有部分研究发现联合SGLT-2抑制剂和RAAS抑制剂在治疗糖尿病肾病方面可能起协同作用,可以进一步延缓肾功能进展,并且不明显增加急性肾损伤、高钾血症、骨折、截肢、尿路感染等风险,但是可能会增加生殖器/泌尿系感染的风险。该文对近年来有关联合该2种药物治疗糖尿病肾病的临床研究进行综述。Diabetic kidney disease is one of the serious complications of diabetes and a common cause of end-stage renal disease.Renin-angiotensin-aldosterone system inhibitor(RAASi)has become a routine treatment for CKD.SGLT-2 inhibitor is a new type of hypoglycemic drug.In recent years,it has been found to have benefits in the kidney and heart.Some studies have found that the combination of SGLT-2 inhibitors and RAAS inhibitors may have a synergistic effect in the treatment of DKD,which can further delay the progression of renal function,and does not significantly increase the risk of acute kidney injury,hyperkalemia,fractures,amputations,urinary tract infections,but may increase the risk of genital or urinary tract infections.This article reviews recent clinical studies on the treatment of diabetic nephropathy with these two drugs.

关 键 词：SGLT-2抑制剂 RAAS抑制剂 ACEI ARB 糖尿病肾病 

分 类 号：R692[医药卫生—泌尿科学]